Is There a Link between Saturated Fat Intake and Alzheimer’s disease? by Konig, Justin
The Science Journal of the Lander College of Arts and Sciences 
Volume 8 
Number 2 Spring 2015 Article 7 
1-1-2015 




Follow this and additional works at: https://touroscholar.touro.edu/sjlcas 
 Part of the Lipids Commons, and the Nervous System Diseases Commons 
Recommended Citation 
Konig, J. (2015). Is There a Link between Saturated Fat Intake and Alzheimer’s disease?. The Science 
Journal of the Lander College of Arts and Sciences, 8 (2). Retrieved from 
This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar. 
It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an 




Alzheimer’s disease is a neurodegenerative disease that causes 
severe memory loss and ultimately death. The first part of the 
brain affected by Alzheimer’s disease is the hippocampus, a region 
of the brain associated with memory. Memory loss is usually the 
first symptom of Alzheimer’s disease. As the disease progresses 
the degeneration spreads to other parts of the brain leading to 
the loss of other cognitive skills such as language skills and the 
ability to plan. Eventually, damage to the basal nucleus of Meynert 
leads to a sharp drop in the amount of the neurotransmitter 
acetycholine present in the brain, leading to further deficiencies 
(Peterson, 2002). Approximately ten percent of the population 
over the age of 65 and fifty percent of those above 85 suffer 
from Alzheimer’s disease (Carlson, 2011). Currently, there is no 
medication that can cure Alzheimer’s disease or stop its progres-
sion. Patients suffering from Alzheimer’s disease are treated with 
medications that alleviate the symptoms. Acetylcholinesterase 
inhibitors are prescribed to alleviate the cognitive symptoms. 
Anxiolytics and antipsychotics may be prescribed to treat be-
havioral symptoms. These drugs, however, may worsen cognitive 
deficiencies. Ultimately, the inexorable progression of Alzheimer’s 
disease leads to death (Peterson, 2002).
Although the cause of Alzheimer’s disease has not been defini-
tively determined, two pathological conditions have been linked 
to Alzheimer’s disease, amyloid plaques and neurofibrillary tan-
gles. The amyloid plaques are extracellular deposits of the pro-
tein beta amyloid (sometimes referred to as amyloid beta). These 
plaques are surrounded by degenerating neurons and activated 
microglia, the phagocytotic cells of the central nervous system. 
Activated microglia are a sign of inflammation or immune re-
sponse. The neurofibrillary tangles are intracellular accumula-
tions of hyperphosphorylated tau proteins. These tangles disrupt 
transport within the neurons eventually killing the cell and leaving 
behind the tangle of filaments (Carlson, 2011). 
Alzheimer’s disease is split into two categories: early onset, also 
called familial, and late onset, also called sporadic. Alzheimer’s 
disease occurring before the age of 65 is considered familial 
whereas Alzheimer’s disease occurring after the age of 65 is con-
sidered sporadic. Familial Alzheimer’s shows a clear pattern of 
inheritance. In different families the disease is caused by different 
genetic mutations. Three genetic mutations have been identified: 
a mutation in the amyloid precursor protein gene (APP) gene, a 
mutation in the presenilin 1 (PS1) and a mutation in the prese-
nilin 2 (PS2) gene. All three of these mutations have been shown 
to increase the relative amount of amyloid beta 42 in the brain. 
Amyloid beta 42 is “stickier” than the wild type variant, amyloid 
beta 40. Consequently, amyloid beta 42 is more likely to con-
glomerate and form plaques. Sporadic or late onset Alzheimer’s 
disease does not show any clear pattern of inheritance. However, 
a variant of the apolipoprotien E gene, apolipoprotein epsilon 
4, has been linked to increased occurrence and earlier age of 
onset of Alzheimer’s disease. Apolipoprotein E is a carrier protein 
for cholesterol. The epsilon 4 variant of this protein has been 
linked to an increase in the amount of amyloid beta in the brain. 
The mechanism behind this relationship is unknown. Researchers 
suspect that apolipoprotein E is involved in the clearance of am-
yloid beta from the brain and that the epsilon 4 variant is not as 
effective the epsilon 2 or epsilon 3 variants in clearing amyloid 
beta (Peterson, 2002). 
Researchers have recently begun to examine the role of diet in 
the etiology of this disease (Heude et al 2003, Kalmijn et al 1997, 
Engelhart et al 2002, Luchsinger et al 2002, Morris et al 2003 
and Laitnen et-al 2006). Diet is a particularly interesting field for 
research because dietary interventions are relatively cheap and 
easy to initiate. This research hopes to provide the public with 
a cost effective method for preventing Alzheimer’s disease, or 
at least delaying its onset. Dietary fats in particular have been 
the focus of much research. The central nervous system has a 
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very high concentration of lipids, second only to adipose tissue. 
Additionally, lack of essential fatty acids has been shown to be a 
limiting factor in brain development (Winocur and Greenwood, 
1993). It follows that intake of fatty acids would have a significant 
impact on the health of the brain later in life. The link between 
apolipoprotien E and Alzheimer’s disease also suggests a role for 
lipid metabolism in the etiology of Alzheimer’s disease. 
Dietary fatty acids are ingested as triglycerides, groups of three 
fatty acids attached by an ester bond to a glycerol backbone. 
In the small intestine, these triglycerides are broken down to 
monoglycerides and fatty acids by the enzyme lipase. After being 
absorbed by the epithelial cells of the small intestine, they are 
recombined to form triglycerides. Because triglycerides are not 
water soluble, they cannot be transported through the blood 
stream without a carrier. Instead, they are combined with pro-
teins to form lipoproteins. Lipoproteins are spherical particles 
with an outer shell of proteins, phospholipids and cholesterol 
surrounding an inner core of triglycerides. There are a number of 
different types of lipoproteins, each with a different composition 
and a different function. The lipoprotein formed in the epithelial 
cells of the intestine is called a chylomicron. The chylomicron 
passes from the intestinal epithelial cells to the lacteal, and is 
delivered to the blood stream via the lymph system (Tortora and 
Derrickson 2006).
Studies have shown that rats raised on a diet high in saturated 
fat were impaired on behavioral tests (Winocur and Greenwood 
1993). Changes in the morphology of the hippocampus consis-
tent with a loss of dendritic integrity and immune response were 
also observed (Granholm et al 2008). Additionally, animals that 
were fed a diet high in saturated fat were found to have higher 
concentrations of the protein amyloid beta (Galloway et al 2007), 
the main component of amyloid plaques, and compromised blood 
brain barrier integrity (Farrall and Wardlaw 2009, Taketchi et al 
2010, Taketchi et al 2013a, Taketchi et al 2013b, and Freeman and 
Granholm 2012). In humans, however, the link between saturated 
fats and Alzheimer’s is not as clear. A number of studies have been 
conducted, and they have yielded conflicting results. This paper 
will review and elucidate the relevant research with the goal of 
answering the following two questions: Is there a definitive link 
between high intake of saturated fat and incidence of Alzheimer’s 
disease? If yes, what is the mechanism of this relationship, and 
does this suggest any possible interventions other than diet 
modification?
Methods
A literature search was conducted using pubmed.gov. The follow-
ing search terms were used: Alzheimer’s disease AND saturated 
fat, Alzheimer’s disease AND dietary fat, Alzheimer’s disease AND 
amyloid beta, Alzheimer’s disease AND blood brain barrier, and 
Alzheimer’s disease AND statins. To exclude irrelevant papers the 
search terms were restricted to the title and abstract. Of the 
papers that were found using these search terms, relevant papers 
were selected based on their abstract. Additional sources of in-
formation were found in the reference sections of these papers.
Discussion
Saturated Fat and Amyloid Beta 
In 1992 Hardy and Higgins proposed that the deposition of am-
yloid plaques is the initiating event in Alzheimer’s disease. This 
hypothesis, called the amyloid cascade hypothesis, suggests that 
an influx of calcium caused by the toxic effects of amyloid plaques 
leads to hyperphosphorylation of the tau proteins which then 
form neurofibrillary tangles and kill the neurons. A number of 
findings support this theory. Firstly, it has been observed that mu-
tations of the gene encoding the tau protein lead to Parkinson’s-
like symptoms, but did not lead to the deposition of amyloid 
plaques. Secondly, it has been observed that mice expressing mu-
tant variations of both amyloid beta and tau protein experience 
increased formation of tau protein tangles when compared to 
mice expressing only the mutant version of tau protein, while the 
number of amyloid plaques is the same. Both of these observa-
tions indicate that the deposition of amyloid plaques leads to the 
formation of tau protein tangles, but not the other way around. 
The discovery that familial Alzheimer’s disease is caused by a ge-
netic mutation in the amyloid precursor protein also supports 
the amyloid cascade hypothesis. It seems likely that both famil-
ial and sporadic Alzheimer’s disease share an underlying cause 
(Hardy and Selkoe, 2002). 
It has been shown that the degree of dementia is correlated with 
the amount of amyloid beta present in the brain (Naslund et. al. 
2000). However, there is no evidence of increased production 
of the amyloid beta protein in the brains’ of Alzheimer’s disease 
patients, indicating that the observed increase is caused by de-
creased clearance of amyloid beta from the brain or increased 
uptake of this protein from circulation (Pallebage-Gamarallage et. 
al. 2009). Using iodine-125 labeled amyloid beta, researchers have 
shown showed that amyloid beta from circulation does indeed 
cross the blood brain barrier (Mackic et. al. 2002) This suggests 
that factors which increase the levels of circulating amyloid beta 
may increase the level of amyloid beta in the brain, and lead to 
the formation of plaques. 
The protein amyloid beta is involved in the metabolism of lipids. 
In vivo, it is associated with chylomicrons and lipoprotein B, and 
it increases the uptake of triglyceride rich lipoproteins (TRLs) 
by fat rich organs (James et. al. 2003). Consistent with this, it has 
been found that a diet high in saturated fat increases the levels 
of amyloid beta in enterocytes (Galloway et. al. 2007). The link 
between lipid metabolism and the deposition of amyloid plaques 
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in the brain is further strengthened by the finding that high serum 
cholesterol induced by high cholesterol feeding is correlated with 
increased levels of amyloid beta in the brain, as well as increases 
in the number and size of amyloid plaques (Refolo, 2000). These 
studies investigated the effect of cholesterol only, but not the 
effect of saturated fat.
The link between saturated fat and amyloid plaques suggests that 
reducing intake of saturated fat would reduce the incidence of 
Alzheimer’s disease. However, it must be noted, that a ketogenic 
diet, a diet very low in carbohydrate content and very high in fat 
content, has been shown to lower the amount of amyloid beta 
in a rat’s brain (Van der Auwera et. al. 2005). This indicates that 
the increase in amyloid beta observed in rats fed a high saturated 
fat diet is not simply because of the high fat content. Rather, it 
is the result of a synergistic effect between saturated fats and 
carbohydrates. 
Saturated Fat and Blood Brain Barrier 
Dysfunction
Saturated fat may also have a detrimental effect on the health of 
the brain by disrupting the blood brain barrier. The blood brain 
barrier was discovered more than 100 years ago by Paul Ehrlich 
when he observed that blue dye injected into an animal’s blood 
stream will not reach the spinal cord or the brain. The blood 
brain barrier is formed by the endothelial cells of the blood 
vessels in the central nervous system. In most capillaries there 
are gaps between the endothelial cells that allow substances to 
diffuse in and out of the blood. In contrast, the endothelial cells in 
the central nervous system are tightly packed, and held together 
by tight junctions. This prevents many substances that normally 
diffuse out of the blood stream from diffusing into the central 
nervous system (Carlson, 2011).
A disruption of the blood brain barrier can lead to Alzheimer’s 
disease through two distinct pathways. As previously mentioned, 
there is evidence that the increase in the amount of amyloid beta 
in the brains of Alzheimer’s patients may be due to an influx of 
amyloid beta from circulation. We previously explored the pos-
sibility that this is because intake of certain lipids increases the 
amount of amyloid beta present in the blood. Another possibility 
is that the influx of amyloid beta is due to the breakdown of the 
blood brain barrier. In addition to affecting the level of amyloid 
beta in the brain, a breakdown of the blood brain barrier would 
allow toxins to enter the brain, possibly leading to Alzheimer’s 
disease through a completely different pathway.  
There are a number of methods by which blood brain barrier 
integrity can be assessed. The levels of plasma derived proteins 
in the brain can be measured, with a greater amount indicat-
ing influx through the blood brain barrier. Similarly, the levels of 
cerebrospinal fluid derived proteins in the plasma can also be 
measured to determine efflux through the blood brain barrier. 
Immunoflourescent antibodies can be used to detect the pres-
ence of tight junction proteins and other proteins integral to the 
maintenance of the blood brain barrier.  Imaging techniques such 
as contrast CT, contrast MRI, and positron emission topography 
(PET) have also been used. 
Whether blood brain barrier dysfunction is linked to Alzheimer’s 
disease has been debated for many years. A number of experi-
ments have been performed using both biochemical and imaging 
techniques. A meta-analysis of sixteen studies found that there 
was a statistically significant link. There was, however, great het-
erogeneity among the results of individual studies (Farrall and 
Wardlaw, 2009). 
To examine the effects of saturated fat on the blood brain barrier, 
researchers examined the brains of mice fed a diet high in satu-
rated fat, high in unsaturated fat and a control group fed standard 
laboratory chow. Immunoglobin G (IgG), and apolipoprotien B 
(a hepatically derived lipoprotein) were used to measure influx. 
The cerebrospinal fluid protein, S100B was used to detect efflux. 
After three months, the mice were euthanized, and the relative 
abundance of occludin, a tight junction protein, was also assessed. 
It was observed that levels of immunoglobin G and apolipopro-
tien B were greatly elevated in the brains of mice in the saturated 
fat group, indicating increased influx of proteins and lipoproteins. 
The increased presence of apolipoprotein B, a lipoprotein that is 
associated with amyloid beta in enterocytes, supports the the-
ory that blood brain barrier dysfunction can cause Alzheimer’s 
disease by increasing the influx of amyloid beta. Plasma levels of 
S100B were also greatly elevated indicating efflux from the cere-
brospinal fluid into the brain. Finally, levels of occludin were found 
to be lower in the saturated fat group, indicating a breakdown of 
the tight junctions that form the blood brain barrier. The effects 
of the high saturated fat diet were exacerbated when the mice 
were examined after six months of feeding (Taketchi et. al. 2010 
and Taketchi et. al. 2013a). 
Another experiment examined the effect of a high saturate fat/
high cholesterol diet on three blood brain barrier proteins. The 
proteins investigated were endothelial barrier protein and the 
tight junction proteins occludin, and ZO-1. Using immunofloures-
cent antibodies the high saturated fat/high cholesterol fed rats 
were found to have markedly less endothelial barrier protein 
in the cortex and the CA-1 region of the hippocampus. When 
analyzed by western blot, a hippocampal homogenate of the ex-
perimental rats was found to have more occludin and the same 
amount of ZO-1 as that of the control rats. However, immu-
noflourescent imaging showed that the localization of occludin 
was markedly different in the two groups. In the control group 
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occludin was found to be present mostly in the walls of blood 
vessels, as would be expected for a blood brain barrier protein. 
In contrast, the blood vessels of the experimental group stained 
very weakly for occludin, while there was a strong signal in axon 
fibers and granule cells of the dentate gyrus. It may be that the 
increased level of occludin detected in the brain of the experi-
mental group was because expression of occludin had been up-
regulated in response to blood brain barrier damage (Freeman 
and Granholm, 2012). 
Saturated Fat and Cognitive Decline in Animals
The evidence linking saturated fat to increased production of 
amyloid beta and blood brain barrier dysfunction suggests a link 
between saturated fat and Alzheimer’s disease. Indeed, a link 
between saturated fat and cognition has been observed in rats. 
Researchers found that rats fed a diet high in saturated fat per-
formed worse on memory tests than rats fed a diet that had 
unsaturated fat as its main fat component (Winocur and Gordon 
1993). Again, it must be noted that rats fed a ketogenic diet did 
not experience any cognitive decline, despite the extremely high 
saturated fat content in their diets. This is consistent with the 
finding that a ketogenic diet reduces the levels of amyloid beta in 
the brain (Van der Auwera et al 2005). 
In addition to memory impairment, researchers found that a 
diet high in cholesterol and saturated fat significantly altered the 
morphology of the hippocampus, one of the areas of the brain 
responsible for memory and learning. After being fed a diet high 
in saturated fat and cholesterol, sections of the hippocampus 
were tested for Map2, an integral membrane protein that is con-
sidered a marker for dendrites, and Iba1 a marker for microglia. 
Compared to the control group, rats fed a diet high in saturated 
fat had significantly less Map2 and considerably more Iba1, in-
dicating a loss of dendritic integrity and activation of microglia, 
both hallmarks of Alzheimer’s disease (Granholm et al 2008).
Saturated Fat and Alzheimer’s Disease
A link between saturated fat and Alzheimer’s disease cannot be 
definitively asserted unless there is evidence of such a link in 
humans. A number of epidemiologic studies have been conduct-
ed to determine the link between dietary fats and Alzheimer’s 
disease (Heude et. al. 2003, Kalmijn et. al. 1997, Engelhart et. al. 
2002, Luchsinger et. al. 2002, Morris et. al. 2003, and Laitnen et. 
al. 2006). Although the information gleaned from these studies is 
enlightening, the results must be approached with caution. All of 
these studies rely on self reporting. Because participants do not 
know how much fat they have ingested, researchers use food 
frequency questionnaires that ask participants about their dietary 
habits. This information is used to estimate their intake of various 
micronutrients. This method is an estimate at best. As with all 
studies relying on self reporting there is an inherent inaccuracy. 
Additionally, responses on a questionnaire reflect only the re-
spondent’s current diet, but offer no information about their di-
etary habits in the past. Discrepancies among these studies can 
arise from differences in the questionnaires used, length of follow 
up time, the age of the population being studied, and the ethnicity 
of the population.  
In the Rotterdam study, 7,983 residents of a suburb of Rotterdam 
over the age of 55 were administered questionnaires that were 
followed up by clinical examinations. After a two year follow 
up, researchers found a statistically significant link between in-
creased intake of saturated fat and incidence of Alzheimer’s dis-
ease (Kalmijn et. al. 1997). Interestingly, the link was significant 
even after eliminating patients with cerebrovascular disease, in-
dicating that the mechanism mediating this link is not vascular in 
nature. However, a six year follow up of the same group showed 
no significant link between saturated fat intake and Alzheimer’s 
disease (Engelhart et. al. 2002). An examination of the methods 
used in the two studies does not reveal an obvious reason for 
this discrepancy. Both studies used the same method of assessing 
dietary intake of fats, and both adjusted their results for similar 
confounding variables. The authors of the second study do not 
address the discrepancy directly, but they do suggest that the 
longer follow up may introduce selective survival. For instance, 
it may be that subjects who live longer are less susceptible to 
the detrimental effects of a high fat diet leading to a longer life 
span, and a lower incidence of dementia as well (Engelhart et. al. 
2002). It may also be that saturated fat lowers the age of onset 
of Alzheimer’s disease, but does not increase overall incidence.
Using data from the Washington Heights-Inwood Columbia Aging 
Project (WHICAP), researchers found a link between total intake 
of fat and increased incidence of Alzheimer’s disease. Saturated 
fat alone was linked to increased incidence of Alzheimer’s disease; 
however, the hazard ratio was slightly lower than that of total fat 
intake and was less than that of monounsaturated fats, indicating 
that saturated fat is not more harmful than other fats. Although 
increased intake of saturated fat overall was linked to increased 
incidence of Alzheimer’s disease, no difference was found be-
tween those reporting moderately high intake and those re-
porting very high intake. When the data was analyzed using only 
people who had tested positive for the apolipoprotien E epsilon 
4 allele (both homozygous and heterozygous) the link between 
total fat intake and Alzheimer’s disease was much stronger and 
successively greater intake of saturated fat indicated successively 
greater risk of Alzheimer’s disease (Luchsinger et al 2002).
Another study using data from the Chicago Aging Project and a 
median follow up of 3.9 years found a strong link between satu-
rated fat and Alzheimer’s disease. Participants in the top fifth of 
saturated fat intake were 70% more likely to develop Alzheimer’s 
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disease. This is in contrast to other fats, some of which seemed to 
lower the risk of Alzheimer’s disease. Adjusting for confounding 
variables led to 120% increase in risk. In contrast to the findings 
of Luchsinger et al (2002), this study found that the link between 
saturated fat and Alzheimer’s disease was not any stronger in par-
ticipants possessing the apolipoprotein E epsilon 4 allele (Morris 
et al 2003). 
The previous studies focused on elderly people and had a follow 
up between two and seven years. A short follow up can poten-
tially underestimate the link because of the possibility of sub-
clinical dementia (i.e. the patients who were discovered to have 
dementia might have had subclinical dementia at baseline, and 
the poor diet is a symptom rather than a cause of the disease). 
In contrast, Laitnen et al (2006) studied the link between fat in-
take at midlife and the incidence of Alzheimer’s disease later in 
life. In this study participants of the CAIDE study who had been 
examined in either 1972, 77, 82, or 87 were called for reexamina-
tion in 1998. The mean follow up was 21 years. This study found 
that participants with moderate fat intake (second quartile) had 
a lower risk of Alzheimer’s disease than either low fat or high 
fat intake. When broken down to specific fats, high polyunsat-
urated fats and monounsaturated fats were correlated with a 
decreased risk of Alzheimer’s disease, while high intake of satu-
rated fats was correlated with a higher incidence of Alzheimer’s 
disease. Only the data for polyunsaturated fats and saturated 
fats yielded results that were statically significant. When adjusted 
for the Apolipoprotien E epsilon 4 allele, the results were sim-
ilar; suggesting that effect of saturated fat is not related to the 
Apolipoprotein E epsilon 4 allele. It is noteworthy that this study 
calculated relative intake of fatty acids based only on intake of 
different types of dairy, excluding two major sources of dietary 
fatty acids, meat and fish.
As previously mentioned, studies that rely on self reporting food 
frequency questionnaires are inherently inaccurate.  To address 
this problem, researchers studied the link between erythrocyte 
membrane content and cognitive decline. This study found a sig-
nificant link between saturated fatty acid content in erythrocytes 
and cognitive decline. Interestingly, the results for polyunsaturat-
ed fatty acids were mixed; n-6 polunsaturated fatty acids were 
linked to cognitive decline while n-3 polyunsaturated fatty acids 
seemed to protect against decline. This study investigated only 
the link between fatty acids and general cognitive decline. A link 
between membrane composition and Alzheimer’s disease specif-
ically was not investigated (Heude et al 2003). 
Lipid-Lowering Pharmaceuticals
The link between saturated fatty acids and Alzheimer’s disease sug-
gests that drugs that lower plasma lipids may prevent Alzheimer’s 
disease, or slow its progression. Probucol is a lipid-lowering agent 
with anti-inflammatory and antioxidant properties that has been 
used to treat cardiovascular disease (Santos, 2012). Experiments 
with mice have shown that Probucol ameliorates the detrimental 
effects of a diet high in saturated fat. It was previously mentioned 
that mice fed a diet high in saturated fat and cholesterol were 
found to have a greater abundance of the protein amyloid beta in 
enterocytes. When Probucol was added to their diet, the levels 
of enterocytic amyloid beta in the saturated fat group were com-
parable to those in the control group (Pallebage-Gamaramllage 
et al 2012). 
It was also found that Probucol prevented the damage to the 
blood brain barrier normally associated with a high saturated 
fat diet. Mice were randomly assigned either to a control diet, a 
diet high in saturated fat, a diet high in cholesterol, or a high sat-
urated fat/high cholesterol diet with Probucol for three months. 
Consistent with previous experiments the mice in the high satu-
rated fat and high cholesterol diets were found to have damage 
to the blood brain barrier as measured by the concentrations of 
immunoglobin G and apolipoprotien B in the brain, and the con-
centration of S100B in the blood plasma. High saturated fat and 
high cholesterol mice were also found to have a greater abun-
dance of activated microglia, a sign of inflammation. However in 
mice treated with Probucol the levels of immunoglobin G, apoli-
poprotein B and S100B were comparable to that of the control 
group. There was also no evidence of inflammation in mice treat-
ed with Probucol (Taketchi et al 2013a). 
When the experiment was repeated and mice were kept on the 
high saturated fat diets for 12 months the effect of the high satu-
rated fat diet on blood brain barrier permeability and enterocytic 
abundance of amyloid beta was even more pronounced. Yet, de-
spite the long term exposure to saturated fat, the group treated 
with Probucol was not effected (Taketchi et al 2014). In addition 
to preventing damage to the blood brain barrier and lowering en-
teroctyic accumulation of amyloid beta, Probucol was also found 
to increase synaptic density in mice (Poirier, 2008). 
A pilot study examined the effect of Probucol on 12 patients with 
mild-to-moderate Alzheimer’s disease. A clinical assessment after 
six months of treatment found that Probucol led to a stabilization 
of symptoms (Poirier, 2008). This was a small scale study that 
did not include a control group. A long term controlled study is 
needed to definitively determine whether Probucol is an effective 
treatment for Alzheimer’s disease and whether its effect is long 
lasting. 
It is possible that the positive effects of Probucol are not related 
to lipid metabolism. Probucol was found to attenuate the effects 
of an injection of amyloid beta in mice. Mice injected with amyloid 
beta exhibited cognitive decline, and a histological examination of 
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their brains shows decreased synaptic density (as measured by 
the presence of the presynaptic protein synaptophysin) and in-
creased acetylcholinesterase activity. Injection with amyloid beta 
does not increase plasma cholesterol. Treatment with Probucol 
for 15 days attenuated the effects of the amyloid beta injection. 
This is despite the fact that the pathological conditions observed 
in these mice were not due to increased lipid intake or dysfunc-
tional lipid metabolism. This suggests that Probucol may directly 
affect the pathway responsible for Alzheimer’s disease patholo-
gy in addition to its positive effect on lipid metabolism (Poirier, 
2008). 
Statins (HMGCoA reductase inhibitors) are another group of 
lipid lowering agents prescribed to treat cardiovascular disease. 
Similar to Probucol, statins also have anti inflammatory proper-
ties. In an experiment similar to that performed with Probucol 
it was shown that treatment with statins will reverse the blood 
brain barrier damage caused by a high saturated fat diet. Mice 
were fed either a low fat diet or a diet high in saturated fat. 
Consistent with previous experiments the mice fed a diet high 
in saturated fat were found to have significantly higher levels if 
immunoglobin G and apoliprotien B in the brain parenchyma, 
an indication of blood brain barrier damage. Treatment for two 
weeks with Atorvastatin, a lipid soluble statin, led to a decrease 
in the amount of immunoglobin G present in the brain. Treatment 
with pravastatin, a water soluble statin did not lead to any re-
duction after two weeks. After eight weeks of treatment it was 
found that both atorvastatin and pravastatin completely negated 
the effects of the high saturated fat diet (Pallebage-Gamarallage 
et al 2012). Unlike other studies, this study tested the effect of 
the experimental compound after the mice had been on the sat-
urated fat diet for an extended period of time. The effectiveness 
of the compounds after the effects of the saturated fat diet had 
presumably set in suggests that statins may be effective at re-
versing damage to the blood brain barrier as opposed to simply 
preventing it. 
 An analysis of data obtained from the General Practice Research 
Database in the UK revealed that individuals who had been pre-
scribed statins had a significantly reduced incidence of Alzheimer’s 
disease. This was true even for individuals who had taken statins 
in the past, but were no longer taking these drugs. Interestingly, 
use of other lipid lowering agents was not correlated with a 
lower risk of Alzheimer’s disease (Jick et al 2000). Another study 
used data from the databases of three different U.S. hospitals. This 
study also found a statistically significant relationship between 
use of lovastatin (Mevacor) or pravastatin sodium (Pravachol), 
and a lower incidence of Alzheimer’s disease. Simvastatin (Zocor), 
a different statin, was not correlated with decreased incidence of 
Alzheimer’s disease in this study (Wolozin et al 2000).  
Ibuprofen, a non-steroid anti inflammatory drug (NSAID) that 
does not have any lipid lowering properties was also tested 
alongside simvastatin and pravastatin in the previously described 
experiment. After two weeks of treatment Ibuprofen was found 
to be as effective as simvastatin, and eight weeks of treatment 
completely reversed the effects of the high saturated fat diet 
(Pallebage-Gamarallage et al 2012). Antioxidants are another 
group of compounds that have been found to ameliorate the 
effect of saturated fat. Inflammation is caused by reactive oxy-
gen species (ROS). Anti oxidants combat the effects of reactive 
oxygen species and prevent inflammation. Four compounds were 
tested: aged garlic extract, alpha-lipoic acid, niacin, and nicotin-
amide. Mice were fed either a low fat diet a high saturated fat 
diet or a high saturated fat diet containing one of the four com-
pounds. All four compounds were found to prevent the blood 
brain barrier dysfunction and inflammation caused by a high satu-
rated fat diet (Takechi et al 2013b). These studies suggest that the 
protective property of statins and Probucol that was observed 
in humans and mice may be related to their anti inflammatory 
properties and not their lipid lowering properties.
Conclusion
Saturated fat is clearly linked to an increase in amyloid beta and 
to blood brain barrier dysfunction in animals. Although not de-
finitive, epidemiologic evidence seems to indicate that increased 
intake of saturated fat is a risk factor for Alzheimer’s disease. 
Based on the evidence presented, it is reasonable to suggest lim-
iting intake of saturated fat as part of an effort decrease the risk 
of Alzheimer’s disease. In particular those with the apolipopro-
tein E epsilon 4 allele should limit their intake of saturated fat. 
However, it must be noted that saturated fat is only one among 
many micronutrients that make up our diet. Saturated fat alone is 
not responsible for inflammation, blood brain barrier dysfunction, 
or deposition of amyloid plaques. In fact, we have cited evidence 
that a ketogenic diet, which is high in saturated fat, reduces the 
amount of amyloid beta in the brain. When designing a diet low 
in saturated fat one needs to ensure that saturated fat is not 
replaced with an equally unhealthy substitute. Furthermore, there 
is no evidence that limiting saturated fat intake after the onset 
of Alzheimer’s disease will reverse or even slow the disease’s 
progression. At best, limiting intake of saturated fat throughout 
the course of one’s life will lower the incidence of Alzheimer’s 
disease and delay its onset, but it will not cure it.
The use of Probucol, statins, and other anti-inflammatory med-
ications in the treatment of Alzheimer’s disease is strongly sup-
ported by the evidence cited. Anti inflammatory medication 
has been shown to reverse damage to the blood bran barrier 
caused by saturated fat. Probucol has been shown to lower en-
terocytic accumulation of amyloid beta and to slow the progres-
sion of Alzheimer’s disease. Use of statins has also been linked 
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to a decreased risk for Alzheimer’s disease. Further research is 
needed to determine which of these drugs is most effective, and 
whether these drugs can be effective in the long term.  
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